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ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL 
LUNG DISEASE: A NATIONAL MULTICENTER STUDY OF 63 PATIENTS 
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ABSTRACT   
Objective: Interstitial lung disease (ILD) is one of the most serious complications of 
rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of 
abatacept (ABA) in patients with ILD associated to RA. 
Methods: National multicenter, non-controlled, open-label registry study of RA patients 
with ILD treated with ABA.  
Results: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy 
were studied. The mean±standard deviation age at the time of the study was 63.2±9.8 
years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, 
respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients 
the development of ILD was closely related to the administration of synthetic or biologic 
disease modifying anti-rheumatic drugs. After a follow-up of 9.4±3.2 months, two thirds 
of patients remained stable whereas one-quarter experienced improvement in the 
Modified Medical Research Council scale. At that time forced vital capacity remained 
stable in almost two thirds of patents and improved in one out of five patients assessed. 
Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two 
thirds and showed improvement in a quarter of the patients assessed. At 12 months, 
50% of the 22 patients in whom chest HRCT scan was performed due persistence of 
respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of 
the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to 
adverse events. 
Conclusion: ABA appears to be an effective in RA-associated ILD. 
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Interstitial lung disease (ILD) is a common and serious complication of autoimmune 
diseases, including rheumatoid arthritis (RA)1,2. The pathogenesis, clinical presentation 
and histopathology of RA-associated ILD (RA-ILD) appears to be similar to that of 
idiopathic interstitial pneumonitis3,4. 
The prevalence of RA-ILD varies from 19 to 44%5-7, and it is an important cause of 
mortality in patients with RA8,9. Currently, it is considered the second cause of death in 
patients these patients, after cardiovascular disease10. Thus, RA-ILD patients have 3-
fold higher risk of death than RA patients without this complication11. 
The management of RA-ILD represents a major clinical challenge. Several 
conventional synthetic and biologic disease-modifying anti-rheumatic drugs (DMARDs) 
had been considered to be involved in the development or in the exacerbations of ILD. 
Methotrexate (MTX), leflunomide (LFN), anti-tumor necrosis factor (TNF)-α agents, 
rituximab (RTX), and tocilizumab (TCZ) have been reported to induce pneumonitis or 
worsen pre-existing RA-associated ILD12-15.  
To date, the optimal treatment for RA-ILD has not yet been established17. Blockade of 
T cell costimulation by the cytotoxic T Lymphocyte Antigen 4 (CTLA-4)-Ig, a soluble 
chimeric fusion protein consisting of the extracellular domain of murine CTLA4 and a 
mouse IgG2a constant region, led to inhibition of lung inflammation in the murine 
hypersensitivity pneumonitis18. However, the experience on abatacept (ABA), an 
antagonist of T-lymphocyte co-stimulation, in patients with ILD associated to RA is 
generally scarce and limited19,20.  
Taking into account all these considerations, in the present study we aimed to 
determine the potential efficacy of ABA in patients with ILD associated to RA. 
 
PATIENTS and METHODS 
Design, Enrollment Criteria and Definitions 
A national multicenter, noncontrolled, open-label registry study of patients with ILD 
associated to RA treated with ABA was conducted. Patients with ILD attending the 
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Rheumatology divisions of 31 centers from Spain between 2000 and 2016 who had at 
least a 3-month follow-up period after starting ABA were assessed. Data were retrieved 
from the clinical records and stored in a computerized database. 
RA was diagnosed according to the ACR 1987 classification criteria21 or the 
ACR/EULAR 2010 criteria22 depending on the year of diagnosis. Seropositive RA was 
considered if the disease was associated to positive Rheumatoid Factor (RF) and/or 
cyclic citrullinated peptide antibodies (CCPA) in at least two different determinations. 
One or two senior radiologists, depending on each Center, performed the assessment 
of the high resolution computed tomography (HRTC) scans of the chest, independently. 
chest HRCT scans were assessed by a systematic review of all lung fields evaluating 
the presence and extent of ground glass attenuation, reticulation, honeycombing, 
decreased attenuation, centrilobular nodules, other nodules, consolidation, and 
emphysema. There were classified in 3 general radiological patterns according to 
standardized criteria of the American Thoracic Society/European Respiratory Society 
International Multidisciplinary Consensus Classification of the Idiopathic Interstitial 
Pneumonias 23. The different pulmonary patterns defined by lung biopsy or chest HRCT 
scans were as follows: a) usual interstitial pneumonia (UIP), b) non-specific interstitial 
pneumonia (NSIP); and c) “other patterns” (bronchiolitis obliterans [BO], organized 
pneumonia [OP] and mixed patterns) 23.  
Disease activity score-28 (DAS28) was evaluated using the erythrocyte sedimentation 
rate (ESR) [DAS28 ESR]. RF was determined by nephelometry; CCPA were detected 
by standard commercial enzyme-linked immunosorbent assays (ELISA). Pulmonary 
function tests were performed based on the 2002 recommendations of the Spanish 
Society of Pneumology and Thoracic Surgery (SEPAR) 24.  
For the inclusion in the present study RA patients had to be treated with at least one 
dose of ABA after the ILD diagnosis. Patients were diagnosed as having ILD based on 
pulmonary function tests and positive chest CT findings or lung biopsy at baseline, 
before receiving treatment with ABA. Nevertheless, in 3 patients FVC test could not be 
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performed because they were critically ill and the time of diagnosis of ILD. In these 3 
patients a diagnosis of ILD was supported by chest HRCT scan results and other 
conditions, such as pulmonary infections and heart failure, were excluded. They also 
received treatment with ABA after the diagnosis of the ILD. Because of that, to provide 
information on the actual spectrum of severity of ILD associated to RA in patients 
undergoing ABA therapy, they also were included in the present study. 
ABA was prescribed at standard intravenous dose (10 mg/kg/4 weeks) or 
subcutaneously (125 mg/week). The time period between baseline chest HRCT scans 
and the ABA onset ranged between 1 and 2 weeks in all the cases. 
 
Outcome Variables 
The efficacy of ABA was evaluated according to the following measurements: a) 
Modified Medical Research Council (MMRC) scale24; b) Pulmonary Function Tests 
(PFT) that were performed following international criteria. We considered as significant, 
changes ≥10% in Forced Vital Capacity (FVC) and diffusing capacity of the lung for 
carbon monoxide (DLCO)25,26; c) Improvement, worsening or stability criteria in HRCT 
scans were evaluated in each center by an experienced radiologist. Confirmation by a 
second senior radiologist was required in doubtful cases, d) DAS28, CRP and/or ESR 
data were also assessed. All these variables were gathered at baseline and, when 
available, assessed at 3, 6 and 12 months of follow-up. 
 
Statistical Analysis 
Results were expressed as mean±standard deviation (SD) or as median [interquartile 
range (IQR), 25th-75th] as appropriate. Wilcoxon's test was used to compare continuous 
variables before and after ABA therapy (at 3, 6 and 12 months). Qualitative variables 
were compared by the Chi-squared test or Fisher test, as appropriate. STATISTICA 
software (StatSoft Inc., Tulsa, Oklahoma, USA) was used for the statistical analysis. 
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RESULTS 
Baseline clinical characteristics at abatacept onset 
We studied 63 patients (36 women/27 men) with RA-associated ILD treated with ABA.  
Baseline features of the series before ABA onset are summarized in Table 1. The 
mean age at ABA onset was 63.2±9.8 years. At that time, the duration of RA and ILD 
from diagnosis were 6.8 (IQR 2-13.6) and 1 (IQR 0.3-3.3) years, respectively. Patients 
were positive for RF or CCPA in 55 (87.3%) and 54 (85.7%) of the 63 cases, 
respectively. In addition to the use of HRCT for the diagnosis of ILD, histological 
confirmation of ILD by lung biopsy was obtained in 18 of 63 patients.  
The most common patterns of RA-associated ILD were UIP (n=29 [43%]) and NSIP 
(n=17 [27%]). Before ILD diagnosis, 59 patients had received synthetic DMARDs and 
19 biologic agents. At the time of the ILD diagnosis, patients were receiving the 
following conventional synthetic and biologic agents: MTX (n=38), LFN (n=15), 
hydroxychloroquine (HCQ) (n=7), etanercept [ETN] (n=7), adalimumab [ADA] (n=3), 
infliximab [IFX] (n=2), certolizumab pegol [CZP] (n=2), azathioprine (AZA) (n=4), 
sulfasalazine (SSZ) (n=1), gold salts (n=1), RTX (n=1) and TCZ (n=1). In 15 (23.8%) of 
63 patients, the development of ILD was closely related to the administration of 
synthetic DMARDs (MTX, n=5 and LFN, n=1) or biologic DMARDS (ETN], n=3, ADA, 
n=3, CZP, n=2 and IFX, n=1).  
Regarding glucocorticoids, the median dose of prednisone at baseline was 10 [5-13.1] 
mg/day.  
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TABLE 1. Baseline clinical features of 63 patients with Rheumatoid Arthritis associated 
with Interstitial Lung Disease treated with abatacept.  
 
 
Age, years, mean± SD     63.2± 9.8 
Sex, female/male      36/27 
Smoker or ex-smoker, n (%)    38 (60.3%) 
Rheumatoid factor 
Positive, n (%)      55 (87.3%) 
Titer, median [IQR] (normal values, U/mL)  316 [140-735] (0-22) 
CCPA 
Positive, n (%)     54 (85.7%) 
Titer, median [IQR] (normal values, U/mL)  330 [248-743] (0-50) 
Duration of RA*, years, median [IQR]                             6.8 [IQR 2-13.6] 
Duration of ILD**, years, median [IQR]                      1 [IQR 0.3-3.3] 
Chest HRCT pattern of ILD, n (%) 
Usual interstitial pneumonia     29 (46%) 
Non-specific interstitial pneumonia   17 (27%) 
Others       17 (27%) 
CCPA: Cyclic Citrullinated Peptide Antibodies; DMARD: Disease-Modifying Anti-
Rheumatic Drugs, HRCT: High Resolution Computed Tomography; ILD: Interstitial 
Lung Disease.  
*Since the disease diagnosis. **From the diagnosis of RA to the diagnosis of ILD. 
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Treatment with abatacept and outcome variables 
ABA was used at standard intravenous dose for RA (10 mg/kg/4 weeks) after an 
induction period with 2 intravenous injections every other week in 26 patients. In the 
other 37 patients, this agent was administered subcutaneously (125 mg/week). These 
numbers did not allow us to draw conclusions on differences in the efficacy of the route 
of administration of ABA. It was prescribed as monotherapy (n= 26) or along with the 
following conventional DMARDs: LFN (n=15), MTX (n= 6), HCQ (n=10), SSZ (n= 4), 
AZA (n=4), chloroquine (CQ) (n=1) and cyclosporine A (CyA) (n=1).  
At the time of ABA onset, the degree of dyspnea using MMRC scale was as follows: a) 
asymptomatic (grade 0 MMRC) (n=19); b) mild dyspnea (grade 1 MMRC) (n=17); c) 
mild-moderate dyspnea (grade 2 MMRC) (n=17); d) moderate-severe dyspnea (grade 
3 MMRC) (n=8) and e) severe dyspnea (grade 4 MMRC) (n=2). At that time, DLCO and 
FVC measurements were performed in 48 and 60 patients with mean± SD values of 
64.4±16.1% and 87.1±15.6%, respectively.  
The number of patients assessed at each time period (baseline, at 3, 6 and 12 months) 
was the following: MMRC: at baseline 63 patients, at 3 months 63, at 6 months 55 
(87% of the 63 assessed at baseline) and 36 patients at 12 months. FVC: at baseline 
60 patients, at 3 months 33, at 6 months 33 (55% of the 60 assessed at baseline) and 
26 patients at 12 months. DLCO: at baseline 48 patients, at 3 months 28, at 6 months 
22 (46% of the 48 assessed at baseline) and 23 patients at 12 months. 
The outcome of these parameters during the follow-up period is detailed in Figure 1. At 
3 months after the onset of ABA therapy, maintained clinical stabilization or 
improvement was seen in most cases. After a mean follow-up of 9.4±3.2 months, the 
following findings were found: a) 1 of 19 patients who were asymptomatic at baseline 
developed mild dyspnea (grade 1); b) about two thirds of patents remained stable 
whereas one-quarter experienced improvement of at least 1 point on the MMRC scale 
(Figure 1A); c) Regarding respiratory function tests, FVC remained stable in almost 
two thirds of patents whereas it showed an improvement of at least 10% from baseline 
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in one out of five patients assessed (Figure1B); d) DLCO remained stable in almost 
two thirds and showed at least 10% improvement in a quarter of the patients assessed. 
(Figure 1C); e) the mean DAS28 ESR score decreased from 5.03±1.42 at baseline to 
3.34±1.25 at month 6 and 3.51±1.24 at month12 (Figure 2). A decrease in the median 
prednisone dose from 10 [5-13.1] mg/day at baseline to 5 [5-7.5] mg/day at month 12 
was also achieved (Figure 3). At 12 months, chest HRCT scans were performed in 22 
patients with persistence of respiratory symptoms. At that time, 11 of 22 patients 
showed stabilization of the ILD radiological features. Radiological improvement was 
found in 8 (36.4%) whereas worsening of the chest HRCT scan pattern was observed 
in 3 cases.  
 
FIGURES 1A, 1B and 1C. Dyspnea (MMRC scale) and lung function tests results 
(FVC and DLCO) at 3, 6 and 12 months in our series 
 
Figure 1A 
 
Figure 1B 
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Figure 1C 
 
 
 Abbreviations (in alphabetical order):  DLCO: Diffusion of the Lung for Carbon 
monoxide; FVC: Forced Vital Capacity; MMRC: Modified Medical Research Council. 
*p<0.05; **p<0.01 vs. baseline. Only the “improvement” variable was considered in the 
calculations. 
 
FIGURE 2. Mean DAS28 ESR score at baseline, at 3, 6 and 12 months.  
 
Bars represent 95% confidence interval (CI). 
**p<0.01 vs baseline values. 
 
 **  **  ** 
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Abbreviations: DAS28: Disease activity score with 28 joints count.  
 
FIGURE 3. Median prednisone dose at baseline, at 3, 6 and 12 months.  
 
 
Bars represent 95% confidence interval (CI). 
**p<0.01 vs baseline values. 
 
Adverse events 
During the follow-up period, ABA had to be withdrawn in 11 of 63 patients. Due to 
inefficacy to improve the rheumatic manifestations in 3 of them (no improvement or 
worsening of DAS28), because of pulmonary worsening and joint inefficacy in 1 patient 
and due to adverse events in 7 patients. The main adverse effects were severe 
respiratory infections (n=2), severe urinary infection (n=1) and serious cutaneous 
infusion reaction (n=1). One patient died during the follow-up due to ischemic heart 
disease. Another patient died two months after ABA withdrawal because of a flare of 
ILD. 
 
** ** 
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DISCUSSION 
We studied 63 patients with RA-associated ILD treated with ABA. We assessed the 
following data: dyspnea, lung function tests (FVC and DLCO) and HRCT findings. Most 
patients yielded stabilization or improvement of these variables.  
The pathogenesis of RA-associated ILD remains unknown. There are several 
predisposing factors such as male gender, older age, and cigarette smoking, that are 
also predictors of mortality27,28. Indeed, cigarette smoking may represent an upstream 
trigger leading to in situ development of citrullinated proteins, which may play an 
important role in both idiopathic pulmonary fibrosis and RA- associated ILD29. 
Association between positivity of RF and CCPA and the development of ILD-RA has 
also been reported26,27,30,31. RF and CCPA have been detected in smokers with ILD 
even without clinical signs of RA29.  
The predisposing factors discussed above are consistent with our data since in our 
series the mean age was 63.1± 9.6 years, more than 40% were men although the 
disease itself is more common in women, 87.3% and 85.7% were RF positive or CCPA 
positive, and 60.3% of them were active smokers or ex-smokers. 
Paulin et al.29 proposed two potential mechanisms to explain the co-existence of RA 
and ILD. An immune response against citrullinated peptides taking place at the joints, 
which subsequently shifts to the lungs, leading to an interstitial lung inflammation, 
mainly to a NSIP pattern32. It was also postulated that individuals with a genetic 
susceptibility to RA may develop an immune response against citrullinated peptides in 
the lung, causing inflammation that subsequently affects the joints33. 
On the other hand, it is well-known that several conventional DMARDs, especially MTX 
and LFN, have been involved in de novo development or in exacerbations of ILD.12,14,15. 
Furthermore, biological DMARDs may be the trigger of severe lung injuries by inducing 
idiosyncratic reactions, accelerating pre-existing ILD, modifying ILD into a more 
injurious phenotype, or increasing the susceptibility to infections20,34,35.  
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Pérez-Álvarez et al.35 published 122 cases of new-onset ILD or exacerbation of ILD 
secondary to administration of biologic therapy, including 108 patients with RA. These 
authors observed that RA-associated ILD occurred in these patients after a mean of 26 
weeks from the onset of the biologic therapy and had a high rate of mortality (29% of 
patients), mainly during the first 5 weeks of treatment. Panopoulos and Sfikakis36 
reported 144 patients of new-onset or exacerbation of RA- associated ILD with the use 
of anti-TNF-α drugs. Nakashita et al.37 reported 58 patients with RA with a pre-existing 
ILD and observed that the incidence of exacerbation of RA-associated ILD was higher 
in patients receiving anti-TNF-α agents (24.1%). Although no increase in the 
prevalence of ILD following TCZ or ABA therapy has been reported, Kawashiri et al.38 
reported a fatal case of exacerbation of ILD during treatment with TCZ. Also, Wendling 
et al.39 reported a patient with acute worsening of pre-existing RA associated to 
pulmonary fibrosis and emphysema after 2 years of the TCZ onset. 
Dixon et al.40 studied 367 patients with pre-existing RA- associated. These authors did 
not find an increase of mortality in patients with RA-associated ILD following treatment 
with anti-TNF therapy when compared with that related to the use traditional DMARDs. 
In our series, following ABA onset, 4 of 9 patients who had suffered ILD related to anti-
TNF-α drugs experienced an improvement of dyspnea (measured by MMRC), and 2 
and 3 of these 4 patients also had improvement of FVC and HRCT scan, respectively. 
The remaining 5 patients remained stable in terms of dyspnea, respiratory function 
tests and radiological findings. 
The role of RTX in RA-associated ILD has been recently questioned due to the report 
of some cases of drug-induced ILD. Hadjinicolaou et al41 performed a systematic 
literature review to document all reported cases of RTX-associated interstitial lung 
disease. A total of 121 cases of potential ILD related with RTX were identified being 
fatal in 18 patients. 
 
   15 
Different radiological patterns of pulmonary involvement associated with RA have been 
described, usually extrapolated from those of idiopathic pulmonary fibrosis23. The 
patterns commonly associated with RA in decreasing frequency are the following: UIP, 
NSIP, BO and OP. Classically, UIP has been associated with lower 5-year survival 
when compared to the other radiological patterns42. In our series, 46% of the patients 
presented with UIP, 27% had NSIP and 27% had other radiological findings including 
OP, OB and mixed patterns. After a follow-up of 12 months, we observed an 
improvement in HRTC scans in 33.3% of patients with UIP, whereas 50% remained 
stable from a radiological point of view.  
The diagnosis and treatment of RA-associated ILD represent a challenge for the 
clinicians for several reasons. First, respiratory infections and drug-induced pulmonary 
diseases need to be excluded. Second, some patients have progressive RA-associated 
ILD while others have a stable disease. This fact implies the need for regular clinical, 
imaging and pulmonary function test monitoring to effectively discriminate between 
these different courses of the disease. Third, the clinical evidence of the efficacy and 
safety of specific drugs for RA-associated ILD is quite limited43. Glucocorticoids have 
been traditionally the first-line treatment for RA-associated ILD. However, the mean 
dose of glucocorticoids in our series was relatively small, so we do not believe that they 
may have influenced the outcome of our patients. In cases of refractory disease, the 
use of other DMARDs such as mycophenolate, azathioprine or cyclophosphamide has 
been reported with controversial results44-46.  
ABA is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to 
the extracellular domain of CTLA-4. It binds human B7 (CD80/86) more strongly than 
CD28. ABA has demonstrated his efficacy on RA in different studies47,48. In 
experimental studies, CTLA-4 has been tested as an important target in lung 
inflammation in other pulmonary diseases such as hypersensitivity pneumonitis. In this 
setting, this biologic agent may be a potential therapy on RA- associated ILD49. 
Unfortunately, only small case series of RA-associated ILD patients treated with ABA 
   16 
have been published19,20,50. Mera-Varela et al.19 reported 4 patients who developed ILD 
or exacerbation of preexisting ILD while they were undergoing anti-TNF-α therapy. 
They were subsequently treated with ABA without deterioration of respiratory function 
tests or remarkable side effects, suggesting that ABA may provide a better control of 
RA in patients with ILD unresponsive to conventional DMARD therapy. In contrast, 
Curtis et al20 performed a retrospective cohort study to evaluate ILD incidence and 
exacerbation among 109 ABA and 59 TCZ new users compared with those on anti-
TNF-α agents. However, these authors did not find significant differences. Recently, 
Nakashita et al.50 reported 16 patients with RA-associated ILD treated with ABA without 
worsening of ILD in any of them. In addition, DAS28-ESR score and serum 
metalloproteinase-3 levels decreased and the dose of glucocorticoids was also tapered. 
Our study has imitations due to its retrospective design, the variable duration of the ILD 
before the onset of abatacept and the relatively short follow-up time. Another potential 
limitation was the absence of a control group. Nevertheless, no prospective studies on 
RA-associated ILD are available.  Moreover, a good number of our patients had clinical 
improvement and they remained stable during the follow-up. Finally, although the 
number of patients in whom a control CT-scan of the chest was performed at 1 year 
may appear to be low, it was only carried out in the patients who at that time had 
clinical manifestations related to the ILD, since in the rest of patients the symptoms 
were stable or had improved.  
Taken together, our findings speak in favor of the potential use of ABA in ILD related to 
RA.  
In conclusion, herein we report one of the largest series of RA-associated ILD patients 
treated with ABA. In this study, ABA seems to be an effective treatment for these 
patients. Large randomized prospective studies are needed to confirm these promising 
results. 
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